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Abstract Tyrosine kinase inhibitors (TKIs) are the
mainstay for treatment of chronic myelogenous leukemia
(CML). Imatinib was the first TKI approved for use in
CML, but resistance to this therapy has emerged as a sig-
nificant issue, and second-line options are often necessary.
Increased-dose imatinib may elicit responses in some
patients, but clinical evidence suggests only a minority
experience sustained benefit. The second-generation TKIs,
dasatinib and nilotinib, have demonstrated efficacy in
patients resistant or intolerant to imatinib. Changes in
therapy, with the aim of inducing durable response, should
occur promptly after imatinib failure is identified as all
agents are more effective in chronic phase disease than in
later stages. Selection of second-line agents should be dri-
ven by efficacy and safety: dasatinib may be more effective
in patients with P-loop or F359C mutations; nilotinib may
be more effective in those with F317L mutations.
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Introduction
Chronic myelogenous leukemia (CML) is characterized by
the presence of the Philadelphia (Ph) chromosome which
encodes the BCR-ABL fusion protein, the causative
molecular aberration in the pathogenesis of the disease [1].
CML is usually diagnosed in the chronic phase (CP), and,
if left untreated, the disease will progress to an accelerated
phase (AP) and, ultimately, to a terminal blast phase (BP)
within 3–5 years [2] (Table 1). Ph is also present in a
subpopulation of patients with acute lymphoblastic leuke-
mia (Ph?ALL).
Tyrosine kinase inhibitors (TKIs) which target BCR-
ABL are the mainstay for treatment of CML. Imatinib was
the first approved BCR-ABL-targeted therapy for use in
CML, and has substantially changed the treatment and
outcomes associated with this disease. Before the intro-
duction of such TKIs, 5-year survival rates with interferon
treatment or chemotherapy were 57 and 42%, respectively
[6]. Imatinib therapy is associated with a 5-year overall
survival rate of 89% [7]. Nonetheless, resistance has also
emerged as a significant clinical issue with this agent and
effective second-line and beyond treatments continue to be
needed and developed. Two second-generation TKIs have
been approved for the treatment of patients with imatinib
resistance or intolerance. Dasatinib was approved for the
treatment of patients with CML that have resistance or
intolerance to imatinib. Nilotinib was approved for the
treatment of patients with CP or AP CML who have failed
prior treatment. In the age of targeted TKI therapy, it is key
to select the appropriate agent at the appropriate juncture
for each patient, the aim being to achieve long-term,
durable responses with minimal toxicity. Here, we discuss
the current treatment options for patients with CML that
have failed imatinib and evaluate the important consider-
ations when designing treatment algorithms.
First-line imatinib
In the pivotal phase III International Randomized Study of
Interferon and STI571 (IRIS) trial, imatinib (400 mg/day)
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showed superior activity compared with the previous front-
line therapy, interferon-a plus low-dose cytarabine, in
patients with newly diagnosed CP CML. The estimated
rates of major cytogenetic response (MCyR; Table 2) at
18 months were 87 and 35% with imatinib and interferon,
respectively. Complete cytogenetic response (CCyR;
Table 2) rates were 76% in the imatinib group and 15% in
the interferon group (P \ 0.001) [9]. At 60 months, 67%
(368/553) of patients treated with imatinib achieved a
CCyR, and overall survival was 89% [7].
Imatinib also has activity in patients with advanced
stage CML, but the therapeutic advantages here are mod-
est: MCyR rates recorded in phase II studies in patients
with AP/BC CML were 16–24% [10, 11]. Three-year
overall survival rates for patients following imatinib failure
have been reported as 72% for patients with CP CML, 30%
for patients with AP CML, and 7% for those with BC
disease [12]. These data underline the importance of pre-
venting disease progression.
A recently published retrospective study in patients with
CP CML receiving first-line imatinib (400–800 mg/day)
has provided direct evidence that durability of response
predicts patient outcome [13]. In this study of 276 patients,
maintenance of a CCyR or major molecular response
(MMR) for C12 months was significantly (P B 0.01)
associated with improved progression-free survival (PFS)
compared with responses lasting less than 12 months. In
total, 78% of patients maintained a CCyR for C6 months,
this figure falling to 71% at C12 months, and 54% at
C24 months. Similarly, the percentages of patients main-
taining a MMR for C6, C12, and C18 months were 54, 43,
and 32%, respectively. In patients receiving the currently
approved first-line dosage of 400 mg/day alone, the rates of
CCyR and MMR durable for 12 months or more were
lower; 59 and 39%, respectively.
Imatinib resistance
Despite the impressive activity associated with imatinib
therapy, resistance has emerged as a serious clinical issue.
Resistance to imatinib is defined as either primary, where
patients are refractory to imatinib treatment, or secondary,
in which a previously achieved response is lost. In the IRIS
trial, approximately 25% of patients were reported to
exhibit some degree of primary resistance to imatinib: an
Table 1 Definitions of accelerated phase and blast crisis CML [3–5]
World health organization criteria International bone marrow transplant registry criteria
Accelerated
phase
• Peripheral blood and/or marrow blasts 10–19%
• Peripheral blood basophils C20%
• Persistent thrombocytopenia (\100 9 109/L) or
thrombocytosis ([1,000 9 109/L) unresponsive to therapy
• Progressive splenomegaly and increasing white blood cell
count unresponsive to therapy
• Cytogenetic evidence of clonal evolution
• Peripheral blood or marrow blasts C10%
• Peripheral blood basophils and eosinophils C20%





• Peripheral blood or marrow blasts and promyelocytes C20%
• Leukocyte count difficult to control with hydroxyurea/
busulfan
• Rapid leukocyte doubling time (\5 days)
• Development of myelofibrosis
Blast crisis • Peripheral blood or marrow blasts C20%
• Extramedullary blast proliferation
• Large blast foci/clusters in bone marrow biopsy
• Peripheral blood or marrow blasts C20%
• Extramedullary leukemic cell infiltrates








Hematologic Complete White blood cell counts
\1 9 109/L plus normal differential; platelet count




Ph? metaphases = 36–95%
Ph? metaphases = 0–35%
Ph? metaphases = 0%
Molecular Major BCR-ABL/ABL ratio \0.10%, or [3-log decrease from baseline
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estimated 5% of patients failed to achieve a complete
hematologic response (CHR) at 3 months, 22% failed to
achieve any cytogenetic response at 6 months, 23% failed
to achieve at least a partial cytogenetic response (PCyR;
Table 2) at 12 months, and 24% failed to achieve a CCyR at
18 months [7, 9, 14]. Secondary resistance was also evident.
After 60 months of follow-up, the estimated relapse rate
was 17% and progression to AP or BP occurred in 7% of
patients [7]. In a second study, intent-to-treat analysis
revealed that the probability of remaining in MCyR at
5 years is 63% (i.e., 37% of patients required alternative
treatment within 5 years of diagnosis) [15]. Similarly, a
large retrospective analysis revealed resistance or intoler-
ance to imatinib in 45% of patients [16]. Therefore, there is
a strong clinical need for further treatment options.
Several mechanisms are likely to underlie the develop-
ment of imatinib resistance. One of the most established
causes of imatinib resistance is the acquisition of point
mutations in the kinase domain of BCR-ABL [10].
BCR-ABL mutations have been reported at a frequency in
the range of 42–90% among patients with secondary
imatinib resistance [17–19]. Mutations emerge more fre-
quently among patients with advanced disease compared
with those with CP disease, and the frequency increases
with disease duration [20]. Furthermore, the presence of
point mutations at baseline has been shown to predict loss
of CCyR on imatinib therapy [15].
Over 40 different imatinib-resistant mutations have been
identified to date [21]. These generally fall within four
regions of the ABL kinase domain, including the ATP
binding loop (P-loop), the contact site (e.g., T315 and
F317), the SH2 binding site (e.g., M351), and the A-loop
[22]. The different BCR-ABL mutations emerge at varying
frequencies which can differ according to the stage of the
disease [21]. The most frequently occurring mutations
(30–40%) are within the P-loop. P-loop mutations confer
high levels of resistance to imatinib and are associated with
poor prognosis [23]. The second most frequently observed
mutation is T315I [23]. This single amino acid substitution
renders BCR-ABL-expressing cells insensitive to imatinib
as well as other clinically available tyrosine kinase inhib-
itors [24]. Of note, these mutations decrease the efficacy of
TKIs in CML, but do not necessarily predict an increase in
the aggressiveness of the clone, and patients with mutations
may have an indolent course [25].
A more recently implicated cause of imatinib resistance
is the constitutive activation of downstream signaling
molecules (e.g., SRC family kinases or SFKs). SFK-
mediated phosphorylation (i.e., activation) of BCR-ABL is
required for full oncogenic activity [26]. Transfection of
myeloid leukemia cells with kinase-defective HCK has
been shown to block BCR-ABL-related cellular transfor-
mation [27].
Further studies indicate that SFK activation is present in
imatinib-resistant CML and that such activation may be
targeted therapeutically. Overexpression of the SFKs, LYN
and HCK, have been reported in CML cell lines exhibiting
BCR-ABL-independent imatinib resistance, and SFK
inhibition in these cells resulted in growth inhibition [28,
29]. A recent report has shown that FYN (another SFK) is
up-regulated by BCR-ABL and that FYN expression cor-
related to the stage of the disease, being significantly
increased in blast crisis cells compared with chronic phase
cells [30]. It is unclear to what degree and with how much
hetero- or homo-geneity CML is addicted to these addi-
tional pathways.
Other proposed mechanisms affecting imatinib sensi-
tivity include altered expression of drug influx and efflux
proteins (i.e., Pgp and OCT-1) [31, 32], BCR-ABL gene
amplification, and overexpression of BCR-ABL [33, 34].
In addition, many patients that develop imatinib resistance
will not have a cause identified.
Response-based indicators of imatinib resistance
To ensure effective patient care in CML, the response to
imatinib therapy is monitored frequently according to for-
mally defined standards (Table 3) [35]. In this manner,
resistance may be detected promptly and treatment chan-
ged, if appropriate. The National Comprehensive Cancer
Network (NCCN) 2008 guidelines for CML recommend
time-based landmark responses to treatment that should be
met if the patient is to continue receiving the same imatinib
schedule: a CHR should be achieved within 3 months, at
least a minor cytogenetic response (Table 2) within
6 months, at least a MCyR within 12 months, and a CCyR
within 18 months of treatment. If these landmarks are not
met then a treatment change should be considered [35].
Results from the IRIS study underscore the importance
of achieving such landmark responses. A retrospective
analysis of outcomes of patients treated with imatinib in this
trial, and those treated with interferon-a plus low-dose
cytarabine in the CML91 trial demonstrated a significant
survival advantage among patients who achieved a MCyR
by 12 months, irrespective of the treatment administered
[36]. Similarly, CCyR was found to be an independent
predictor of survival and the key prognostic indicator in
CML [8, 36, 37]. There are a number of prerequisites for
gaining a CCyR. A hematologic response is a prerequisite
for attaining a CCyR and also for long-term survival [38].
The degree of preceding cytogenetic response is also cru-
cial. In the IRIS trial, the probability of eventually
achieving a CCyR was only 15% if the karyotype at
6 months was [95% Ph chromosome-positive. Further-
more, if the response after 12 months of treatment was less
Oncol Rev (2009) 3:59–70 61
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than a MCyR, the probability of achieving a CCyR at
2 years was\20% [8]. In addition to the non-achievement
of time-based landmark responses, loss of a previously
achieved response or progression to advanced phase disease
should also trigger a change in treatment [35]. It should also
be noted that the NCCN provides criteria that define partial
resistance and suggests that treatment should be reassessed
in these cases, even in absence of outright failure (subop-
timum responses). In such cases, the patient may continue
to benefit from the current treatment schedule, but long-
term outcome may improve under an alternative strategy.
Evidence is now emerging to suggest that time-based
response landmarks earlier than those proposed by the
NCCN are warning signs in patients unlikely to achieve
long-term benefits from imatinib, in particular the failure to
achieve an early cytogenetic or molecular response. For
example, patients in the IRIS trial who did not achieve a
CCyR with imatinib by 12 months had a significantly
higher risk of disease progression than patients with such a
response [7]. Equally, not achieving a cytogenetic response
at 3 or 6 months was associated with lower overall survival
and PFS compared with patients who reached these
responses [37, 39–42]. A recent retrospective study has
showed that not achieving a MCyR by 6 months is pre-
dictive of decreased overall survival [13]. Nevertheless,
some patients without achieving a CCyR may have disease
control for years. Long-term, prospective studies are nee-
ded to define the optimum cues for TKI changes in the
absence of overt resistance or progression.
In terms of molecular response, patients who fail to
achieve a 1-log reduction at 3 months, or a [2-log reduc-
tion by 6 months in BCR-ABL transcript levels are
unlikely to subsequently achieve a substantial response and
are at high risk for disease progression [24, 43]. Achieve-
ment of a MMR by 12 months appears to provide maximal
protection from disease progression. Five-year follow-up
data from the IRIS study revealed that no patient who
achieved a MMR by 12 months had progressed to
advanced disease [7]. Patients who had both a CCyR and
MMR at 12 months of imatinib therapy had a 100%
probability of remaining progression-free at 24 months as
compared with 95% for patients who had a CCyR and a
\3-log reduction of BCR-ABL transcripts, and 85% for
patients who did not achieve a CCyR [44]. However, the
degree of molecular response in patients already in CCyR
is not associated with differences in survival outcome [13].
In contrast, a rise in BCR-ABL transcripts can serve as an
early indicator of the development of resistance, but a
single test showing an increase in transcripts should not
prompt a change in treatment [21, 45–47]. Emergence of
imatinib-resistant BCR-ABL mutations at any time during
treatment is equivalent to a diagnosis of disease progres-
sion and should prompt a change in therapy [35].
Approved second-line TKI-based treatments: results
from clinical trials in patients with imatinib-resistant
or -intolerant CML
Patients who fail first-line imatinib therapy should be
considered for a change in treatment. Current guidelines for
CML provide three options: high-dose imatinib, dasatinib,
or nilotinib [35]. Key factors that may influence the choice
of agent used are given in Table 4.
High-dose imatinib
Some mechanisms of imatinib resistance may be overcome
by dose escalating imatinib. Certain BCR-ABL mutations
confer intermediate levels of resistance to imatinib [50,
51]. Imatinib resistance caused by BCR-ABL overexpres-
sion may also be overcome using higher doses of imatinib
[52]. Studies have shown that dose escalating imatinib can
Table 3 NCCN monitoring guidelines for patients with CML receiving TKI therapy [35]
Time point of response Monitoring measures
Diagnosis • Bone marrow cytogenetics (or FISH analysis of peripheral blood)
• Measurement of BCR-ABL transcript levels
During apparent response to therapy • Measurement of BCR-ABL transcript levels every 3 months
• Bone marrow cytogenetic analysis at 6 and 12 months, and at 18 months if CCyR
not achieved by 12 months
At CCyR • Measurement of BCR-ABL transcript levels every 3 months
• Bone marrow cytogenetic analysis every 12–18 months in case of clonal abnormalities
Treatment failure, or during AP/BC stage CML • BCR-ABL mutation analysis
Rising (C1 log) BCR-ABL transcript levels • Repeat measurement of BCR-ABL transcript levels in 1 month
• Monthly measurement of BCR-ABL transcript levels, if rise confirmed
• Consider BCR-ABL mutation analysis
62 Oncol Rev (2009) 3:59–70
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induce responses in some patients who relapsed or were
refractory to standard doses, with most benefit observed in
patients who had suboptimal responses, while those who
fail treatment rarely benefit [53, 54]. High-dose imatinib
rarely results in deep, durable responses. Studies indicate
that MCyRs are only gained by 26–38% of patients [53,
54]. Moreover, any responses gained are typically short-
lived, best attained cytogenetic responses being soon lost
by 43–50% of patients [54, 55]. Furthermore, almost all
(93%) patients who do not achieve any cytogenetic
response on standard-dose imatinib do not benefit from a
high-dose regimen [53, 55]. Also, many patients were
intolerant of high-dose imatinib and dose reductions were
required in 41% of patients [53].
Dasatinib
Dasatinib overcomes most forms of imatinib resistance. It
has activity against all BCR-ABL point mutations except
T315I and unlike imatinib, dasatinib can bind multiple
conformations of BCR-ABL and is a potent inhibitor of the
SFKs associated with BCR-ABL-independent imatinib
resistance [56, 57]. In contrast to imatinib, dasatinib is not
a substrate for P-glycoprotein (Pgp) efflux pump, and
OCT-1 does not significantly influence dasatinib uptake
[58]. Dasatinib has 325-fold greater potency versus imati-
nib against BCR-ABL and therefore may also overcome
imatinib resistance mediated by increased expression of
BCR-ABL [33, 34].
Dasatinib has been assessed in a phase II development
program: Src-ABL Tyrosine Kinase Inhibition Activity
Research Trials (START). Four single-arm trials were
initiated in adult patients with imatinib-resistant or imati-
nib-intolerant leukemias: START-C (CP CML), START-A
(AP CML), START-B (myeloid BC CML), and START-L
(lymphoid BC CML and Ph?ALL). One prospective ran-
domized trial, START-R, evaluated a dasatinib arm and a
high-dose imatinib arm in patients who were previously
resistant to standard-dose imatinib.
In patients with CP CML after 24 months of follow-up,
dasatinib induced CHRs and MCyRs in 91 and 62% of
patients, respectively [59]. Most MCyRs observed were
complete cytogenetic remissions, observed in over half of
patients (53%). MMRs were also achieved in 47% of patients
[59]. With relatively limited follow-up responses seem to be
durable. At 15 months, the PFS rate was 90, and 97% of
patients who had achieved a MCyR maintained it up to this
time point [60]. After a 24-month follow-up, PFS was 80%
(75% in imatinib-resistant and 94% in imatinib-intolerant
patients); 88% of patients who had achieved a MCyR having
maintained it to this time point. Also at 24 months, OS was
94% (92% in imatinib-resistant and 100% in imatinib-
intolerant patients) [59]. Dasatinib has also shown marked
activity in patients with AP or BP CML [61, 62]. In patients
with AP CML, the MCyR rate at 24 months was 40, and 61%
Table 4 Factors affecting the choice of second-line TKI for the treatment of CML [48, 49]
Agent Contraindications Boxed warnings Key warnings and precautions Key BCR-ABL mutations
(resistance or low efficacy)
Imatinib None None • Edema and fluid retention
• Cytopenias




• Bullous dermatologic reactions
[40; including P-loop (e.g.,
Y253F/H, E255 K/V),
contact site (e.g., T315I),
SH2 binding site, and A-loop
Dasatinib None None • Myelosuppression
• Bleeding related events
• Fluid retention
• QT prolongation









• QT prolongation and sudden deaths







CHF congestive heart failure
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of patients achieving a MCyR maintained this response at
24 months. The median PFS was 19.5 months [63]. Though
associated with a significantly lower response rate, deep and
durable responses were also noted at 24 months in patients
with BC CML [64]. But the majority of patients with BC
CML do not have a sustained clinical benefit from dasatinib
or other TKI-based therapy and should be considered for
allogeneic stem cell transplantation.
The START-R study compared dasatinib with high-dose
imatinib (800 mg/day) in patients with CP CML and
resistance to imatinib 400–600 mg/day [65]. After
24 months of follow-up, dasatinib was superior to high-dose
imatinib for rates of MCyR (53 vs. 33%; P = 0.017), CCyR
(44 vs. 18%; P = 0.003), MMR (29 vs. 12%; P = 0.028),
and PFS (86 vs. 65%; P = 0.001) [66]. Responses were also
more durable in the dasatinib arm; 90% of patients receiving
dasatinib maintained MCyR at 18 months compared with
74% of patients receiving imatinib [66].
In the START program, dasatinib demonstrated efficacy
in patients with all imatinib-resistant BCR-ABL mutations
tested, including P-loop mutations (where similar efficacy
to wild type BCR-ABL is observed), except for T315 l [61,
62, 67]. In the START-R study, higher rates of MCyR were
observed in both mutation-positive and mutation-negative
patients receiving dasatinib as compared with those
receiving high-dose imatinib. Furthermore, only dasatinib
induced responses in patients with P-loop mutations [65].
A report evaluating response to dasatinib by baseline BCR-
ABL mutation phenotype among patients enrolled in the
START-C study confirmed activity across a range of
mutants, including those in the P-loop, but also suggested
that patients with F317L mutations may have diminished
responses to dasatinib [68].
Dasatinib is generally well tolerated. Most adverse
events (AEs) were grade 1–2 and resolved either sponta-
neously or with appropriate supportive care. Pleural
effusions (all grades, 23%; grade 3–4, 5% at 70 mg BID;
all grades, 10%; grade 3–4, 2% at 100 mg daily) and grade
3–4 cytopenias (neutropenia 46%, thrombocytopenia 41%,
and anemia 18%) can occur with dasatinib. These AEs can
usually be managed with dose interruption or reduction
[48]. Additionally, diuretics and/or steroids (prednisone
20 mg po daily 93 days) and occasionally thoracentesis
may be indicated in the management of dasatinib induced
pleural effusions [35, 69]. Additionally, 10% of CP patients
experienced hypophosphatemia in clinical studies [48].
There was no evidence of cumulative toxicity on long-term
therapy [67]. As for all approved TKI treatments for CML,
dasatinib is metabolized via the hepatic CYP3A4 cyto-
chrome system. Care should therefore be taken when
dasatinib is taken in conjunction with other agents that
interact with this system.
Based on the data from the START program, dasatinib
was approved for treated imatinib-resistant and -intolerant
patients across all phases of CML (and Ph?ALL) at a
dosage of 70 mg twice daily. Results from a recent phase
III dose-optimization study recently prompted a change in
the recommended daily dose for patients with CP CML
[70].
The rationale for performing the dose-optimization
study derived from two clinical observations. First, in the
phase I study of dasatinib, CHRs and MCyRs were
achieved at total daily doses of 100 and 140 mg with both
once daily and twice daily treatment regimens [71]. Sec-
ond, the median delivered dose in the phase II program in
CP CML patients was approximately 100 mg/day. It was
therefore decided to compare once and twice daily regi-
mens at total daily doses of both 100 and 140 mg. After a
minimum follow-up of 6 months, similar response rates
were seen across all four dasatinib arms (CHRs in 86–
92%; MCyRs in 54–59%; CCyRs in 41–45%). PFS at
6 months was 92% for dasatinib 100 mg once daily and
89% for dasatinib 70 mg twice daily [70]. No significant
difference was apparent between regimens also after a
follow-up of 12 months (MCyRs in 56–63%) [70].
Twelve-month data also indicate that the 100 mg once
daily schedule also has activity across all BCR-ABL
mutations, except T315I.
Differences between regimens evaluated in the dose-
optimization study were apparent, however, in terms of
safety [70]. In the 100 mg once daily arm, there was a
significantly lower frequency of grade 3–4 thrombocyto-
penia compared with the 70 mg twice daily arm (22 vs.
37%; P = 0.004). Frequencies of anemia, leukocytopenia,
and neutropenia were also less, but these reductions were
not statistically significant (P [ 0.05). Pleural effusions
(all grades) also occurred less frequently with dasatinib
100 mg once daily (7 vs. 16%; P = 0.028). Improved
safety with the 100 mg once daily schedule was also
reflected by the lower incidences of dose interruption (51
vs. 68%), reduction (30 vs. 55%), and discontinuation (16
vs. 23%) relative to the 70 mg twice daily schedule.
Results of this study demonstrate that, compared with
the previously recommended 70 mg twice daily dose, a
100 mg once daily regimen offers a more favorable overall
benefit–risk assessment in chronic phase CML. A separate
trial in advanced phase patients showed that a once daily
dose had a better safety profile with similar response rates;
however, further follow-up is necessary before a change in
treatment practice can be recommended [72]. The current
prescribing information for dasatinib now recommends
regimens of 100 mg once daily for the treatment of CP
CML and 70 mg twice daily for the treatment of AP or BC
CML, and Ph?ALL [48].
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Nilotinib
Nilotinib is an analog of imatinib, 10- to 50-fold more
potent than its parent compound against BCR-ABL, which
has recently been approved for the treatment of patients
with CP or AP CML who have failed prior treatment. In
vitro evidence shows that nilotinib has activity against all
imatinib-resistant BCR-ABL mutations except T315 l, but
that activity against P-loop mutations and other imatinib-
resistant mutations, including F359C, may be diminished
[56, 73]. Inhibitory plasma concentrations of nilotinib can
usually be obtained for the majority of P-loop mutations
and further in vivo evidence is needed.
Second-line nilotinib 800 mg/day has been assessed in
an open-label phase II trial in patients with CP CML [74].
After 18 months of follow-up, CHRs were achieved in
85% of patients, MCyRs in 57%, and CCyRs in 41%. In
total, 84% of patients who achieved a MCyR maintained it
for 18 months [75]. A time to progression analysis showed
that 64% of patients had not progressed at 18 months [75].
The overall survival rate at this time point was 91% [75].
These results are similar to those seen with dasatinib in the
START-C trial.
Activity of nilotinib 800 mg/day in patients with AP
CML was demonstrated in a phase II study [76]. After a
follow-up of at least 12 months, MCyRs were achieved in
31% of patients [77]. At 12 months the percentage of
patients who were progression-free was 57%, and the
overall survival rate was 81%.
In the pivotal phase II study in patients with CP CML,
nilotinib showed activity in patients harboring many
imatinib-resistant BCR-ABL mutations (except T315I),
and also in patients with resistance not associated with
BCR-ABL mutations [74]. However, a sub-analysis of this
study of the occurrence of baseline BCR-ABL mutations
and their effect on treatment outcome after 12 months of
treatment showed that no patient with Y253H, E255 K/V,
or F359C/V mutations achieved a CCyR; though the
number of patients with each mutation is relatively low,
making definitive conclusions difficult [64]. These findings
were supported in evaluations of patients enrolled in phase
II clinical studies of nilotinib, which also showed that
Y253F/H, E255 K, and E255K/V mutations were associ-
ated with disease progression [78, 79]. The P-loop
mutations Y253H and E255 K/V are also among those that
most frequently develop during nilotinib treatment and are
associated with disease progression [78, 80].
The AEs associated with nilotinib therapy are predom-
inantly mild to moderate in severity [74]. The incidences of
grade 3–4 thrombocytopenia and neutropenia were similar
to that observed with the dasatinib 100 mg once daily [77].
Nilotinib’s specificity for the ABL kinase and comparably
minimal inhibition of c-KIT and PDGFR also alters its
toxicity profile. Inhibition of PDGFR is thought to be the
cause of the edema associated with imatinib and dasatinib
therapy [81]. In clinical trials only 10% of patients taking
nilotinib have had peripheral edema and none have had
grade 3–4 events [82]. There is minimal cross-intolerance
with imatinib, although approximately half (49%) the
patients with hematologic intolerance to imatinib experi-
enced a recurrence of the grade 3–4 hematologic event
(mostly thrombocytopenia) during nilotinib therapy [83].
Notably, the prescribing information for nilotinib con-
tains a black box warning regarding the risk of QTc
prolongation and sudden death. It should be noted that
prolongation of QTc occurs with both imatinib and dasat-
inib, although sudden death was not observed with these
agents in clinical trials.
QTc prolongation was observed on clinical studies with
nilotinib and sudden deaths occurred that were believed to
be related to ventricular repolarization abnormalities. If
QTc prolongation does occur, treatment should be inter-
rupted; dose reductions or discontinuation may also be
necessary. Additionally, as with all ABL TKIs concomitant
medication should be reviewed [82].
Nilotinib treatment may also be associated with bio-
chemical abnormalities. Increases in serum lipase,
bilirubin, alanine or aspartate aminotransferases, and
alkaline phosphatase have been reported [82]. If these AEs
occur, treatment should be withheld until serum levels
return to grade B1. Treatment can then be resumed at a
reduced dosage (400 mg/day). Hyperglycemia and elec-
trolyte abnormalities [i.e., hypophosphatemia (10%),
hypokalemia (1%), hyperkalemia (4%), hypocalcemia
(1%), and hyponatremia (3%)] can also occur with nilotinib
[82]. However, these electrolyte abnormalities may also
occur with dasatinib in a similar proportion of patients [48,
82]. The prescribing information for nilotinib also carries
contraindications for hypokalemia and hypomagnesemia
due to these abnormalities potential worsening of QTc
prolongation [82]. Nilotinib, like imatinib and dasatinib, is
metabolized via the hepatic CYP3A4 cytochrome system,
and caution should be taken when dasatinib is administered
in conjunction with other compounds which interact with
this system.
When to switch from imatinib to second-line TKI
Data from clinical trials has demonstrated that second-line
TKIs are most effective in extending survival when
administered in CP rather than in the advanced phases of
CML. Three-year survival rates for imatinib-resistant
patients decrease as a function of disease status; 72% for
CP, 30% for AP, and 7% for BC [12]. Furthermore, PFS
was improved when dasatinib was used upon loss of
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cytogenetic response during imatinib treatment versus loss
of hematologic response [84]. Current consensus guide-
lines recommend switching from imatinib to a second-
generation TKI if (1) a CHR is not achieved by 3 months,
(2) no cytogenetic response by 6 months, (3) minor or no
cytogenetic response is achieved by 12 months, (4) a par-
tial cytogenetic response is not achieved by 18 months, or
(5) on disease progression to AP or BC CML.
Use of second-line TKIs in the first-line
Given the clinical benefit gained with dasatinib and nil-
otinib following imatinib failure, the possibility arises that
earlier and deeper responses could be achieved with first-
line use. Current evidence demonstrates that responses in
patients with CP CML are greater than those in patients
with advanced disease [12]. Moreover, patients in late CP
are at greater risk of progression than patients with early
CP CML. The contribution of BCR-ABL mutations during
therapy is also an important issue as genetic instability
increases with progression, making the disease more dif-
ficult to treat. As second-line agents are effective against a
larger spectrum of BCR-ABL mutations than imatinib, the
emergence of resistance may decrease if these agents are
used earlier. Two clinical trials based at the M.D. Anderson
Cancer Centre in Houston, Texas are currently evaluating
first-line therapy with these agents. Early data for a small
number of patients are available.
First-line dasatinib (100 mg/day) administered on a
once- or twice-daily regimen is being investigated (n = 40;
accrual ongoing) [85]. Preliminary results show that CCyRs
were achieved in 94% of patients at 6 months, and in
all evaluable patients (100%) at 12 months. Nilotinib
800 mg/day elicited similar activity [86]; CCyR rates at
6 and 12 months were 100%. Both drugs elicited signifi-
cantly (P \ 0.001) deeper responses at these time points
than imatinib (historical controls) [85, 86]. Marked supe-
riority over imatinib in this setting can also be demonstrated
by comparing the response rates discussed above with those
obtained for first-line imatinib in the IRIS study; after
18 months of follow-up in this trial the CCyR rate was 74%
[9]. But until these trials are reported with sufficient follow-
up, imatinib remains the standard of care for the first-line
management of CP CML.
Third-line tyrosine kinase inhibitors
Resistance and intolerance to currently approved agents
have necessitated the development of further compounds
for the treatment of CML. Of note, there is a particular
need for agents that are active in patients carrying the
T315I BCR-ABL mutation, which is resistant to imatinib
and both second-line TKIs [56]. Selected major develop-
ments are discussed below; a comprehensive review is
beyond the scope of this article.
Bosutinib (SKI-606) inhibits both BCR-ABL and Src,
being 10- to 20-fold more potent against BCR-ABL than
imatinib in vitro, but has no activity against the T315I
mutation [87, 88]. From preliminary data from a study in
imatinib-resistant patients with CP CML, CCyRs were
achieved by 30% of patients [89]. Activity in advanced
stage CML and Ph?ALL has also been demonstrated [90].
A phase III comparison of bosutinib and imatinib in
newly diagnosed patients with CML is currently in
recruitment.
INNO-406 is another dual BCR-ABL and SFK inhibitor,
55-fold more potent than imatinib in vitro, but also has no
activity against T315I [91]. However, activity including
CCyRs has been observed in an ongoing phase I dose-
finding study in patients with CML (any phase) or Ph?ALL
resistant or intolerant to first- or second-line treatment,
including dasatinib or nilotinib [92]. Aurora kinase inhib-
itors are a new class of compound that may provide
successful treatment for patients with T315I-mutated CML.
PHA-739538 is an aurora kinase inhibitor with strong
antiproliferative activity against CD34? cells taken from
untreated CML patients and also from imatinib-resistant
patients, including those with T315I [93]. A phase II study
in patients with CML is now in progress [94]. Seven
patients are currently enrolled, six of whom have T315I
mutations. To date, two patients with T315I mutations have
achieved cytogenetic responses, one of them a CCyR. The
development of another aurora kinase inhibitor, MK-0457,
was recently stopped following concerns over cardiotox-
icity. Omacetaxine mepesuccinate (homoharringtonine;
HHT) is a multi-targeted protein synthase inhibitor. This
compound is currently in phase II development in imatinib-
resistant patients with CML (all phases) and who carry
T315I-mutated BCR-ABL [95]. To date, 29 patients have
been enrolled, 17 of which have CP CML. Preliminary data
indicate a CHR rate of 45% in CP CML patients. Cyto-
genetic responses have been reported in 27% of patients
with CP CML; two responses were CCyRs. Reversion of
T315I status in some patients has also been observed.
Finally, the addition of rapamycin to current TKI ther-
apy may constitute a novel approach to the treatment of
patients with refractory disease. The mammalian target of
rapamycin (mTOR) is constitutively activated in BCR-
ABL-transformed cells, and rapamycin inhibits the growth
of CML cells obtained from patients with imatinib-resistant
disease [96]. Recently, hematologic activity for this com-
pound has been demonstrated in leukemic patients [97].
66 Oncol Rev (2009) 3:59–70
123
Conclusions
Targeted therapy with TKIs has dramatically changed the
prognosis for patients with CML. Despite the impressive
activity of imatinib, resistance to this therapy has become a
significant clinical issue. Dasatinib and nilotinib are both
effective in patients following imatinib failure or intoler-
ance. High-dose imatinib may be effective in some patients
following resistance to standard-dose imatinib, but dasati-
nib has been shown to be more efficacious. Careful
consideration should be taken when deciding which TKI to
select following imatinib failure. Currently, there is no
definitive evidence for the superiority of either dasatinib or
nilotinib in CP or AP CML. Dasatinib is the preferred agent
in BC CML. Treatment decisions should be directed by
both efficacy and safety parameters (Table 4). In particular,
based on pre-clinical and clinical data, patients with certain
P-loop mutations such as Y253F, E255V, and F359 may
respond better to dasatinib; in contrast, patients with the
point mutation F317L may respond better to nilotinib.
Patients at risk for complications from fluid retention may
be better suited to nilotinib. For each of these second-line
TKIs, it may be more beneficial to administer them earlier
in the disease course in order to minimize the emergence of
resistance and improve the overall duration of response.
Trials are currently underway to evaluate this hypothesis.
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